Develops and commercializes therapies for brain disorders, immune-oncology, and gastrointestinal diseases, focusing on novel approaches.
PureTech Health plc, a clinical-stage biotherapeutics company headquartered in Boston, Massachusetts, specializes in discovering, developing, and commercializing innovative medicines across a spectrum of challenging medical conditions. The company's robust pipeline targets diverse therapeutic areas including inflammatory, fibrotic, immunological diseases, as well as intractable cancers, lymphatic and gastrointestinal disorders, and neurological conditions. Its portfolio features cutting-edge therapies such as KarXT for schizophrenia and psychosis in Alzheimer's disease, regenerative biology platforms for conditions like androgenetic alopecia, and immunomodulation treatments for chronic inflammatory disorders.
PureTech Health plc pioneers novel approaches in healthcare, leveraging platforms such as oral therapies derived from the human microbiome, hematopoietic stem cell-based therapies for blood cancers, and voice-based technology for early detection of health changes. Additionally, the company is advancing technologies for the oral delivery of biologics and vaccines, underscoring its commitment to enhancing treatment accessibility and effectiveness. Collaborating with leading pharmaceutical entities like Boehringer Ingelheim and Eli Lilly, PureTech continues to expand its capabilities and accelerate the development of transformative therapies.
Founded in 2015, PureTech Health plc exemplifies a forward-thinking approach to healthcare innovation, integrating scientific expertise with strategic partnerships to address unmet medical needs globally. With a focus on pioneering science and patient-centered solutions, the company remains dedicated to improving outcomes for patients grappling with complex and underserved diseases.